Choroidal Neovascularization Clinical Trial
Official title:
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
The primary objective:
*To measure the difference in the number of Ranibizumab therapies needed in 12 months in the
Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative
group.
Secondary Objective:
- To measure the mean change in visual acuity from Baseline to Month 12.
- To measure the mean change in central retinal thickness per OCT from Baseline to Month
12
This is an open-label study, of intravitreally administered Ranibizumab in eyes with
Age-related Macular Degeneration (AMD), specifically looking at the correlation between the
presence of Posterior Vitreous Detachment(PVD) and the number of intravitreal injections of
Ranibizumab required. 40 subjects from the offices of Vision Research Foundation will be
enrolled in this study. Subjects will be assigned to either a Posterior Vitreous Detachment
(PVD) positive group or a Posterior Vitreous Detachment (PVD) negative group based on a
pre-treatment ultrasound. A maximum of 20 subjects in each group will be enrolled. Subject
accrual into the trial is expected to be completed within 6 months.
All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for
four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits
monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed
basis, based on predefined criteria. Eyes will be evaluated with a full ocular examination,
visual acuity measurement (ETDRS chart at a distance of 4 meters),OCT,FA,Fundus Photos,
B-scan Ultrasound and subject adverse event monitoring.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
| Withdrawn |
NCT01666236 -
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
| Completed |
NCT02015351 -
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
|
N/A | |
| Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
| Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
| Completed |
NCT04075188 -
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
|
N/A | |
| Not yet recruiting |
NCT05055973 -
OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.
|
||
| Recruiting |
NCT00568191 -
Stratus Versus Cirrus OCT in AMD
|
N/A | |
| Recruiting |
NCT00100087 -
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
|
Phase 1/Phase 2 | |
| Completed |
NCT04455399 -
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
|
N/A | |
| Terminated |
NCT02857894 -
Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)
|
||
| Not yet recruiting |
NCT02934841 -
Conbercept in Choroidal Neovascularization Secondary to Uveitis
|
Phase 2 | |
| Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
| Completed |
NCT00775411 -
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT00604071 -
Sensitivity of the Home Macular Perimeter (HMP)
|
N/A | |
| Withdrawn |
NCT00403156 -
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT00406250 -
Intravitreal Bevacizumab in Agioid Streaks
|
Phase 1 | |
| Active, not recruiting |
NCT00599820 -
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
|
Phase 3 |